NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 121 filers reported holding NURIX THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30,513,503 | -21.3% | 3,882,125 | 0.0% | 0.18% | -21.4% |
| Q2 2023 | $38,782,429 | +12.5% | 3,882,125 | 0.0% | 0.22% | +19.1% |
| Q1 2023 | $34,473,270 | -19.1% | 3,882,125 | 0.0% | 0.19% | -26.6% |
| Q4 2022 | $42,625,733 | -15.7% | 3,882,125 | 0.0% | 0.26% | -22.7% |
| Q3 2022 | $50,584,000 | +2.8% | 3,882,125 | 0.0% | 0.33% | +18.6% |
| Q2 2022 | $49,187,000 | +43.1% | 3,882,125 | +58.2% | 0.28% | +40.9% |
| Q1 2022 | $34,382,000 | -51.6% | 2,454,082 | 0.0% | 0.20% | -42.8% |
| Q4 2021 | $71,046,000 | -3.4% | 2,454,082 | 0.0% | 0.35% | +7.1% |
| Q3 2021 | $73,524,000 | +12.9% | 2,454,082 | 0.0% | 0.32% | +12.9% |
| Q2 2021 | $65,107,000 | -14.7% | 2,454,082 | 0.0% | 0.29% | -13.6% |
| Q1 2021 | $76,297,000 | +29.7% | 2,454,082 | +37.2% | 0.33% | +49.1% |
| Q4 2020 | $58,820,000 | -5.8% | 1,788,921 | 0.0% | 0.22% | -11.2% |
| Q3 2020 | $62,451,000 | – | 1,788,921 | – | 0.25% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 327,123 | $4,583,000 | 10.17% |
| TRV GP III, LLC | 1,922,549 | $26,935,000 | 7.31% |
| Ponoi Management, LLC | 327,122 | $4,583,000 | 5.95% |
| Foresite Capital Management IV, LLC | 1,030,798 | $14,441,000 | 4.04% |
| DAFNA Capital Management LLC | 543,344 | $7,612,000 | 1.98% |
| Soleus Capital Management, L.P. | 1,011,638 | $14,173,000 | 1.83% |
| Bain Capital Life Sciences Investors, LLC | 1,284,313 | $17,993,000 | 1.75% |
| Redmile Group, LLC | 3,018,784 | $42,293,000 | 1.32% |
| WestHill Financial Advisors, Inc. | 283,333 | $3,969,000 | 1.14% |
| Boxer Capital, LLC | 1,224,892 | $17,161,000 | 0.88% |